PDL BioPharma Story Overview

PDLI -- USA Stock  

USD 2.55  0.01  0.39%

Macroaxis News
  
By David Taylor

PDL BioPharma is an interesting company.  They really do not make anything.  Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.  Their market capitalization is $365 million and the stock is trading at $2.20 per share.  

Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.  Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.  They are a middleman for the pharma patent industry.  

 

Pharmaceutical Products
Fama & French Classification
A company that buys pharmaceutical patents and then leases them out.

PDL Pharma finds patents for pharmaceutical companies and the leases them out.  It is a small, but growing, niche business.  This firm has positive earnings.  However, because of its uniqueness, the company's stock has been left alone.  It is trading in single-digit EPS.  




PDL BioPharma is an interesting company.  They really do not make anything.  Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.  Their market capitalization is $365 million and the stock is trading at $2.20 per share.  

Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.  Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.  They are a middleman for the pharma patent industry.  

The companies assets have been increasing over the past several years:

2012:     $275

2013:     $537

2014:     $929

2015:  $1,000

This means that the company’s revenue stream will also continue to increase. But, what has been most eye-catching to me is its earnings per share over the same period:

2012:  $1.52

2013:  $1.89

2014:  $2.04

2015:  $2.04

Keep in mind the price of the stock is trading at $2.20 per share.  Essentially, you are getting 1:1 ratio on your investment, and unheard of return on investment in the financial markets.  The earnings are strong and they are generally growing.  Assets are growing as well.  And, yet, the company’s stock is trading at a paltry ratio for EPS.  And, this is not an industry thing.  The industry and the sector averages are extremely healthy when you look at their ratios, respectively:  29.13 & 28.68.  If this stock were to be trading at these averages, the stock would increase in value by a massive 14-times.  That puts the stock trading at $28.00 per share.  

I have looked everywhere to figure out what it was that kept this stock down so low, but there is no indicators that say why PDLI has been left behind like it has.  And, the healthcare industry has been very strong over the past several years, what, with the Baby-Boomers reaching retirement age and that age where their healthcare needs increase significantly.  

The economy, in general, continues to expand, yet another reason that this company will be doing well in the future.  Our Federal Reserve has been increasing interest rates over the past several months to normalize interest rates.  This will also have an added benefit to push the revenue of this company forward.  The spread on future earnings is going to be increased with inflation and interest rate increases.  

But, management’s ability to utilize and resell its assets has been impressive as it continues to increase its revenue by licensing out the patents.  By doing this, reselling the same patent multiple times, the company increases its revenue stream without having to create additional costs.  The company’s position as one of the leaders in this aspect of the pharma industry enables them to build up their base further and further.  Continually, the company leverages its assets and improves its earnings potential.

You would be hard pressed to find another stock at this low of an EPS ratio.  This may be the single most discounted stock I have found to date.  With an economy that is expanding, a stock market that is trading at a high ratio, as well as this particular industry, it is a very difficult thing to pass up on picking up this stock.  Holding on to this stock in your portfolio for a very long time would end up being highly rewarding.  Once the market starts looking at the ratios and then they find this stock, PDLI will be pushed much, much higher. 

Story Momentum

This media report from Macroaxis distributed on February 13, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 2.67% . The trading delta at closing time when the story was published against the current closing price is 13.33% .

Similar stores for PDL BioPharma

Notable Stocks to Keep Your Eyes on Cypress Semiconductor Corporation, , PDL BioPharma, Inc ...news
Global Export Lines Time to Get Greedy With Cypress Semiconductor Stock Motley FoolFull coverage
few days ago at http://hillaryhq.com 
Dillon Associates Has Raised By 559680 Its Facebook Holding PDL Biopharma Has 0.78 Sentiment
news
Hillary HQ Average True Range under Review PDL BioPharma, Inc. , GAIN Capital Holdings, Inc ... Stocks News Point PDL BioPharma, Inc. Analysts See 0.06 EPS ALTURA MINING LTD ORDINARY SHARES AUSTR Full coverage
over a week ago at http://www.stocksnewspoint.com 
Return on Equity Evaluation PDL BioPharma, Inc. , China Rapid Finance Limited NYSEXRF ...
news
Stocks News Point PDL Biopharma Inc Institutional Investors Sentiment Index Crashed in Q1 2018 Florida Recorder PDL Biopharma Inc Shifting Institutional Investors Sentiment SC Daily Full coverage
over two weeks ago at www.macroaxis.com 
Sale by Mcdade Mark of 10000 shares of PDL BioPharma
Macroaxis News
Filed transaction by Pdl Biopharma Inc director. General open market or private sale of non-derivative or derivative security
over two weeks ago at http://globalexportlines.com 
Wobbling Stocks PDL BioPharma, Inc., , General Dynamics Corporation,
news
Global Export Lines Are These Stocks A Sure Bet PDL BioPharma, Inc. , The Trade Desk, Inc. StockNewsGazetteConfounding Stocks Macys, Inc. , PDL BioPharma, Inc. , Aflac Incorporated The Stock Street Full coverage
over three weeks ago at http://stockspen.com 
Active Mover PDL BioPharma Inc
news
Stocks PenFull coverage
over three weeks ago at http://productioninvestments.com 
Extremely Informative stocks Nutanix, Inc. , PDL BioPharma, Inc.
news
Production Investments Full coverage
over a month ago at http://www.thestocksnews.com 
Take a look at Price Fluctuations PDL BioPharma, Inc.
news
The Stocks News Full coverage
over a month ago at www.macroaxis.com 
Acquisition by Yanai Shlomo of 54348 shares of PDL BioPharma subject to Rule 16b-3
Macroaxis News
Filed transaction by Pdl Biopharma Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over a month ago at http://stocksmarketcap.com 
Most Recent Figure Make This Stock Even More Attractive PDL BioPharma Inc
news
Stocks Market CapFull coverage
over a month ago at http://www.thestocksnews.com 
Where PDL BioPharma, Inc. stock is Headed Exactly
news
The Stocks News Full coverage
over three months ago at http://stocksmarketcap.com 
Eye-Catching Hot Stock PDL BioPharma Inc
news
Stocks Market CapGreen stock of the month PDL BioPharma, Inc. stock performed 17.97 The Stocks News Mind-blowing Stocks PDL BioPharma, Inc., NASDAQ PDLI, Apple Hospitality REIT, Inc., DailyNyseNews Full coverage
over three months ago at http://www.wallstreetinvestorplace.com 
One Stock for Low Risk Investors PDL BioPharma, Inc.
news
Wallstreet InvestorplaceSEC FORM 4 - SEC.gov SEC.govCisco Systems, Inc. Zacks.comFull coverage

Compare PDL BioPharma

Compare PDL BioPharma To Peers

Number of Shares Shorted

Number of Shares Shorted Comparative Analysis
  Number of Shares Shorted 
      PDL BioPharma Comparables 
PDL BioPharma is currently under evaluation in number of shares shorted category among related companies. Number of Shares Shorted is total amount of shares that are currently sold short by investors. When stock is sold short, the short seller assumes the responsibility of buying the stock back at a lower price. The speculator will make money if the stock goes down in price or will experience loss if the stock price goes up.
Additionally take a look at PDL BioPharma Hype Analysis, PDL BioPharma Correlation and PDL BioPharma Performance. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.